Key result
Pharmacy-based HbA1c testing is linked to ~2-fold higher digital diabetes prevention program engagement vs GP referral.
Why the study?
Does a pharmacy-based point-of-care HbA1c testing pathway improve detection of prediabetes and engagement with a digital prevention programme compared to GP-based identification in high-risk adults?
Observational (n=1,450)
Yes
Does a pharmacy-based point-of-care HbA1c testing pathway improve detection of prediabetes and engagement with a digital prevention programme compared to GP-based identification in high-risk adults?
Answers are grounded in this paper and cite their sources.
Community pharmacy-based point-of-care HbA1c testing effectively identifies prediabetes and undiagnosed T2D in underserved populations, doubling engagement with digital prevention programs compared to standard GP pathways.
Aims Early detection of type 2 diabetes (T2D) and prediabetes is critical to reduce disease burden, yet disadvantaged populations often remain undiagnosed. We assessed a pharmacy‐based pathway using verified point‐of‐care HbA1c testing to identify prediabetes and enable engagement with a digital prevention programme and established the detection rates for undiagnosed T2D. Methods We conducted a prospective feasibility study across 16 community pharmacies in NHS Tayside, Scotland (Feb 2024–Jan 2025). Adults at high risk of T2D, identified using the Diabetes UK ‘ Know Your Risk ’ tool, were offered HbA1c testing. Participants with HbA1c 42–47 mmol/mol (6.0–6.4%) were referred directly to a digital diabetes prevention programme (DDP); those with HbA1c ≥48 mmol/mol (6.5%) were advised to attend their GP. Comparator data were drawn from GP patients identified for engagement with the same DPP. Results Of 499 pharmacy participants, 75 (15%) had prediabetes; 38 (51%) enrolled in DPP. Nineteen (4%) had HbA1c ≥48 mmol/mol (6.5%); 17 attended GP. Compared with GP‐identified prediabetes (951 patients; 212 enrolled, 32%), pharmacy‐based recruitment doubled DDP engagement (RR 2.08, 95% CI 1.61–2.67). Pharmacy recruited relatively younger participants from more deprived backgrounds (63% SIMD 1–2 vs. 33% in GP cohort). Conclusion Community pharmacies provided effective, equitable access to HbA1c testing and diabetes prevention, identifying individuals with prediabetes and undiagnosed T2D being missed by current pathways and doubling engagement of this underserved population with DPP. Pharmacy‐based screening offers a scalable opportunity to reduce health inequalities and expand primary care capacity.
No takes yet. Share an insight, caveat, or question.
Radley et al. (2026) conducted an observational in Prediabetes and undiagnosed type 2 diabetes (n=1,450). Pharmacy-based point-of-care HbA1c testing pathway vs. GP-based identification was evaluated on Engagement with a digital diabetes prevention programme (DPP) (RR 2.08, 95% CI 1.61-2.67). A community pharmacy-based HbA1c testing pathway doubled engagement with a digital diabetes prevention program compared to GP-based identification.
Synapse has enriched 10 related papers. Consider them for comparative context: